Middle East Pharmaceutical Industries (4016) Stock Overview
Engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for 4016 from our risk checks.
4016 Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Middle East Pharmaceutical Industries Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س59.95 |
| 52 Week High | ر.س79.09 |
| 52 Week Low | ر.س53.89 |
| Beta | 0.49 |
| 1 Month Change | 0.59% |
| 3 Month Change | 2.05% |
| 1 Year Change | -13.72% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4016 | SA Pharmaceuticals | SA Market | |
|---|---|---|---|
| 7D | 1.6% | -2.7% | -1.1% |
| 1Y | -13.7% | -1.0% | 7.0% |
Return vs Industry: 4016 underperformed the SA Pharmaceuticals industry which returned 1.7% over the past year.
Return vs Market: 4016 underperformed the SA Market which returned 7.7% over the past year.
Price Volatility
| 4016 volatility | |
|---|---|
| 4016 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in SA Market | 7.8% |
| 10% least volatile stocks in SA Market | 2.7% |
Stable Share Price: 4016 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4016's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 731 | Mohammed Maher Al-Ghannam | www.avalonpharmaceutical.com |
Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. Its product portfolio includes dermatological, respiratory, cardiovascular, alimentary and anti-infectives, musculoskeletal, genitourinary systems, and CNS.
Middle East Pharmaceutical Industries Company Fundamentals Summary
| 4016 fundamental statistics | |
|---|---|
| Market cap | ر.س2.08b |
| Earnings (TTM) | ر.س104.51m |
| Revenue (TTM) | ر.س493.25m |
Is 4016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4016 income statement (TTM) | |
|---|---|
| Revenue | ر.س493.25m |
| Cost of Revenue | ر.س187.22m |
| Gross Profit | ر.س306.03m |
| Other Expenses | ر.س201.52m |
| Earnings | ر.س104.51m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.99 |
| Gross Margin | 62.04% |
| Net Profit Margin | 21.19% |
| Debt/Equity Ratio | 19.9% |
How did 4016 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 05:16 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Middle East Pharmaceutical Industries Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | SNB Capital |